Qiagen (NYSE: QGEN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Qiagen Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Qiagen Company Info
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
News & Analysis
Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?
The molecular diagnostics company blew past Wall Street's top- and bottom-line expectations in the first quarter for one main reason.
Multiple companies have gained regulatory approvals in recent days.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
There's no shortage yet, but the FDA is working to address supply issues with a key component of COVID-19 diagnostics tests.
The diagnostic-test maker is being acquired for $11.5 billion.
The stock market was turbulent Tuesday morning.
The world's leading provider of scientific tools will buy QIAGEN and its growing menu of molecular diagnostic products.
QGEN earnings call for the period ending September 30, 2021.
QGEN earnings call for the period ending March 31, 2021.
QGEN earnings call for the period ending December 31, 2020.
QGEN earnings call for the period ending December 31, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.